Expanded reporting for drug assistance programs

Summary#

SB 1528, titled “Relating to health care,” would amend Oregon’s prescription-drug reporting law, ORS 646A.689. Its stated goal is to expand drug manufacturers’ annual reporting about patient assistance programs; it did not become law because it failed.

  • Manufacturers would have to report information about each patient assistance program they offered or funded that helped Oregon consumers in the previous calendar year—not only programs tied to drugs that met the law’s price-increase reporting threshold.
  • The report would include participation numbers, the value of assistance, refill limits if applicable, how long assistance is available, and eligibility rules and verification.
  • The report would be due by March 15 each year. Existing rules for department requests for more information, possible civil penalties, and public posting would apply.
  • The bill says these changes would become operative January 1, 2028. Because the bill failed, they do not take effect.

What it means for you#

  • Drug manufacturers: If the bill had become law, manufacturers would have had to report on a wider set of assistance programs, including programs they funded. They would not have to report a program under this change unless it helped consumers residing in Oregon during the previous calendar year.
  • Consumers: The bill would not change drug prices, eligibility for assistance, or the amount of assistance. It would expand what information the department collects and generally posts online, subject to existing limits on disclosing trade secrets.
  • The department: It could request supporting documents or more information under existing rules. The bill does not create a new application or review process for consumers.

Money#

No cost information is in the available material.

  • The bill requires manufacturers to report additional information, but gives no estimate of their reporting costs or the department’s costs.
  • It does not set a fee, tax, or new appropriation.

What is unclear#

  • The supplied bill text does not include the full parent Act, so I could not independently verify all current law. Its marked-up text shows the existing reporting rule was limited to manufacturer-offered programs for drugs that met the price-increase reporting threshold.
  • “Patient assistance program” is defined as a program a manufacturer offers to the general public. The amendment also covers programs a manufacturer “funded”; it is unclear how that applies when a manufacturer funds a program it does not offer.
  • The bill does not say how the department would verify reported information or how it would handle overlap between programs.
  • The bill failed, so it does not set a start date that will bring these changes into effect.

Case for#

  • A possible argument for the bill is that reporting across more assistance programs could give the state and public a broader picture of help available to Oregon consumers.
  • Reporting participation, assistance amounts, and eligibility rules could make it easier to understand how these programs operate.
  • Including programs a manufacturer funds could capture assistance that might otherwise fall outside the reporting requirement.

Case against#

  • Manufacturers would face added reporting work, but the bill does not estimate the cost or explain how much detail reporting would require.
  • The bill does not clearly explain which third-party programs count when a manufacturer funds but does not offer them.
  • Public posting may make program information more visible, but some information could be withheld as a trade secret; the bill does not guarantee that all reported details will be public.

Votes

2 recorded votes on this bill, newest first.

  1. Division No. 1643522

    Passed27 members voted

    Senate Third Reading

    FOR · 17AGAINST · 10

    Each dot is one member. Hover or tap one to see who.

    17For

    • Democratic17

    10Against

    • Republican9
    • Democratic1

    3 members were paired and sat out the vote.

  2. Division No. 1634694

    Passed5 members voted

    Senate Committee Do pass with amendments. (Printed A-Eng.)

    FOR · 3AGAINST · 2

    Each dot is one member. Hover or tap one to see who.

    3For

    • Democratic3

    2Against

    • Republican2